Vimarsana
Biggest News Aggregation in the World

Page 31 - Grant Date News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Grant Date. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Grant Date Today - Breaking & Trending Today

Investegate |Litigation Cap. Mgmt Announcements | Litigation Cap. Mgmt: Incentive Awards - Vimarsana News

Investegate |Litigation Cap. Mgmt Announcements | Litigation Cap. Mgmt: Incentive Awards

Investegate announcements from Litigation Cap. Mgmt, Incentive Awards

Wishpond Provides Corporate Update on the Completed Integration of its Viral Loops Acquisition and Resulting Growth - Vimarsana News

Wishpond Provides Corporate Update on the Completed Integration of its Viral Loops Acquisition and Resulting Growth

/PRNewswire/ - Wishpond Technologies Ltd. (TSXV: WISH) (OTCQX: WPNDF) (the "Company" or "Wishpond"), a provider of marketing-focused online business solutions,...

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Sarepta Therapeutics (NASDAQ:SRPT) - Press Release - Vimarsana News

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Sarepta Therapeutics (NASDAQ:SRPT) - Press Release

CAMBRIDGE, Mass., Sept. 30, 2022 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. SRPT, the leader in precision genetic medicine for rare diseases, gran

Sarepta Therapeutics Announces Inducement Grants Under - Vimarsana News

Sarepta Therapeutics Announces Inducement Grants Under

CAMBRIDGE, Mass., Sept. 30, 2022 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare...

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Vimarsana News

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

01.10.2022 - CAMBRIDGE, Mass., Sept. 30, 2022 (GLOBE NEWSWIRE) - Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on September 30, 2022 that were previously approved by the Compensation ...